Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs

JAMA. 2008 Mar 26;299(12):1474-6. doi: 10.1001/jama.299.12.1474.
No abstract available

MeSH terms

  • Azetidines / therapeutic use*
  • Biomarkers
  • Clinical Trials as Topic*
  • Drug Approval*
  • Ezetimibe
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Quinolines / therapeutic use*
  • Risk
  • United States
  • United States Food and Drug Administration

Substances

  • Azetidines
  • Biomarkers
  • Hypolipidemic Agents
  • Quinolines
  • torcetrapib
  • Ezetimibe